MT 8554Alternative Names: MT8554
Latest Information Update: 22 Feb 2017
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neurological disorders; Vasomotor symptoms
Most Recent Events
- 01 Jan 2017 Mitsubishi Tanabe Pharma Corporation completes a phase I trial for Vasomotor symptoms in Germany (unspecified) (NCT02803268)
- 01 Jun 2016 Phase-I clinical trials in Vasomotor symptoms in Germany (unspecified route) (NCT02803268)
- 01 Mar 2016 Mitsubishi Tanabe Pharma completes a phase I pharmacokinetics trial in Healthy volunteers in United Kingdom (NCT02675309)